TCIM
APLS

TIAA CREF Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History

TIAA CREF Investment Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.29M Sell
66,345
-3,767
-5% -$59.2K ﹤0.01% 2202
2018
Q4 		$925K Sell
70,112
-2,054
-3% -$31.5K ﹤0.01% 2315
2018
Q3 		$1.28M Sell
72,166
-40,869
-36% -$755K ﹤0.01% 2330
2018
Q2 		$2.49M Buy
113,035
+93,746
+486% +$2.15M ﹤0.01% 2050
2018
Q1 		$426K Buy
19,289
+3,460
+22% +$68K ﹤0.01% 2809
2017
Q4 		$343K Buy
+15,829
New +$233K ﹤0.01% 2910

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

TIAA CREF Investment Management's APLS Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Apellis Pharmaceuticals (APLS) stake by 5.4% in Q1 2019, selling an estimated $59.2K and leaving 66,345 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2202.

TIAA CREF Investment Management first reported a position in APLS in Q4 2017 and has held it in 6 quarters since. The position peaked at $2.49M in Q2 2018. 92 funds tracked by Wall St. Rank hold APLS as of Q1 2019.

  • TIAA CREF Investment Management held 66,345 shares of Apellis Pharmaceuticals worth $1.29M as of Q1 2019.
  • TIAA CREF Investment Management sold 3,767 Apellis Pharmaceuticals shares in Q1 2019, an estimated $59.2K.
  • Apellis Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2202 holding.
  • TIAA CREF Investment Management first reported a position in Apellis Pharmaceuticals in Q4 2017 and has held it in 6 quarters since.
  • TIAA CREF Investment Management's Apellis Pharmaceuticals position peaked at $2.49M in Q2 2018.
  • 92 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.